Promising combo tackles rare spine tumor
NCT ID NCT02989636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests the safety of combining an immunotherapy drug (nivolumab) with or without precise radiation (stereotactic radiosurgery) in 21 people with chordoma that has returned or spread. The goal is to see if this combination causes fewer side effects and helps control the tumor. Participants must have confirmed chordoma and evidence of disease progression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill stall advanced sarcomas?
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- New drug shows promise for rare spine cancer
- New gene therapy offers hope for advanced cancers
- Targeted drug shows promise for rare bone cancer
- New proton therapy could shrink skull tumor treatment to just 5 days